德國總理默茨：歐盟貿易工具不得削弱競爭優勢。

Idorsia said on Nov. 4 daridorexant (brand Quviviq) received FDA Breakthrough Therapy designation for treating insomnia disorder in children aged 10 to under 18. There is currently no FDA‑approved drug therapy for pediatric insomnia. Daridorexant was approved in China last year for adult insomnia. Simcere Pharmaceutical (02096.HK) holds exclusive Greater China development and commercialization rights.

Samsung Electronics and SK Hynix fell sharply in early trade as investors worried that tighter US regulation of data centers and AI infrastructure after the US midterm elections could pressure semiconductor shares and weigh on sentiment toward Korean chip names. Kiwoom Securities said the impact on data‑center projects already under way, existing supply contracts and downward revisions to earnings expectations for AI‑infrastructure suppliers would likely be limited.